Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3124 |
Carbendazim
Bavistin,Carbendazole,多菌灵,Mercarzole |
Antifungal | Microbiology/Virology |
Carbendazim (Mercarzole) 是一种具有抗肿瘤活性的苯并咪唑衍生物,可用于癌症研究。它是一种口服广谱苯并咪唑杀菌剂,可作为真菌疾病研究的杀虫剂。 | |||
T26978 |
CEP-40125
RXDX-107 |
DNA Alkylation | DNA Damage/DNA Repair |
CEP-40125 (RXDX-107) 是一种 DNA 烷基剂,可用于研究晚期实体瘤。 | |||
T76706 |
Varlilumab
CDX-1127 |
TNF | Apoptosis |
Varlilumab (CDX-1127) 是一种新型的人 IgG1 抗 CD27 单克隆抗体。Varlilumab 具有抗肿瘤活性,可用于研究晚期实体肿瘤。 | |||
T79157 |
Pimicotinib
ABSK021,ABSK-021 |
c-Fms; Others | Others; Tyrosine Kinase/Adaptors |
Pimicotinib (ABSK021) 为一种有效的 CSF1R 抑制剂,具抗肿瘤活性,可用于研究晚期实体瘤。 | |||
T36395 |
Trotabresib
CC-90010 |
Epigenetic Reader Domain | Chromatin/Epigenetic |
Trotabresib (CC-90010) 是一种具有口服活性的 BET 抑制剂,可用于晚期实体瘤的研究。 | |||
T40199 |
Tulmimetostat
CPI-0209 |
Histone Methyltransferase | Chromatin/Epigenetic |
Tulmimetostat (CPI-0209) 是一种具有口服活性的 EZH1/EZH2 抑制剂。Tulmimetostat 有抗肿瘤活性,用于研究卵巢癌和晚期实体瘤。 | |||
T2113 |
PHA-793887
PHA 793887,PHA793887 |
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
PHA-793887 是一种ATP 竞争性的CDK 抑制剂,可抑制 Cdk2、Cdk1、Cdk4 和 Cdk9 的活性,IC50值分别为 8 nM、60 nM、62 nM 和 138 nM,同时可抑制糖原合酶激酶 3β,IC50值为 79 nM。 | |||
T77750 |
Rosmantuzumab
OMP-131R10 |
Others | Others |
Rosmantuzumab (OMP-131R10) 是一种 人源化抗 R-spondin 3 (RSPO3)单克隆抗体。Rosmantuzumab 具有潜在的抗肿瘤活性,可用于研究晚期复发难治性实体瘤。 | |||
T2709 |
TAK-901
TAK901 |
JAK; CDK; Src; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
TAK-901是一种多靶点的极光激酶抑制剂,对极光激酶 A 和 B 的 IC50值分别为 21 和 15 nM。它用于研究淋巴瘤、骨髓纤维化、多发性骨髓瘤、骨髓化生和晚期实体瘤等治疗的试验。 | |||
T77138 |
Ragifilimab
INCAGN-01876,INCAGN-1876,CM-701 |
TNF | Apoptosis |
Ragifilimab (INCAGN-1876),一种针对糖皮质激素诱导的TNFR相关蛋白(GITR)的单克隆抗体激动剂,适用于晚期或转移性实体瘤的研究。 | |||
T83970 |
IMMH 010 maleate
YPD-30 maleate |
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
IMMH 010 maleate (YPD-30 maleate) 是一种可口服的程序性细胞死亡配体 1 抑制剂,具有潜在的抗肿瘤活性,可用于研究神经系统疾病和晚期恶性实体瘤。 | |||
T6084 |
Rabusertib
LY2603618,IC-83 |
Chk; PDK; Autophagy | Autophagy; Cell Cycle/Checkpoint; PI3K/Akt/mTOR signaling |
Rabusertib (IC-83) 是一种有效的选择性的Chk1抑制剂,IC50为 7 nM。它有潜在的化学增强活性,用于各种癌症和肿瘤治疗的试验。 | |||
T0078L |
Lapatinib ditosylate monohydrate
Lapatinib ditosylate monohydrate,Lapatinib ditoluenesulfonate monohydrate,Lapatinib tosilate hydrate,Lapatinib tosilate,Tykerb,二甲苯磺酸拉帕替尼单水合物,Tyverb |
EGFR; Ferroptosis; Autophagy | Angiogenesis; Apoptosis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Lapatinib ditosylate (Lapatinib tosilate) monohydrate 是一种有效的 EGFR 和 ErbB2 抑制剂,对 EGFR 和 ErbB2的 IC50值分别为 10.8 和 9.2 nM。它用于治疗晚期乳腺癌和其他实体瘤。 | |||
T11500L |
GSK3368715 dihydrochloride
EPZ019997 dihydrochloride,GSK3368715 2HCl,EPZ019997 2HCl |
Histone Methyltransferase | Chromatin/Epigenetic |
GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) 是一种具有口服活性和高效性的 I 型蛋白精氨酸甲基转移酶 (PRMTs) 抑制剂 ,具有抗癌和抗肿瘤活性,抑制PRMT1,PRMT3,PRMT4,PRMT6,PRMT8的活性,可用于研究晚期实体肿瘤。 | |||
T6157 |
Devimistat
CPI-613,辛酸,CPI613,CPI 613,6,8-Bis(benzylthio)octanoic acid |
Apoptosis; Dehydrogenase; Mitochondrial Metabolism | Apoptosis; Metabolism |
Devimistat (6,8-Bis(benzylthio)octanoic acid) 是一种线粒体代谢抑制剂,还是一种lipoic acid 拮抗剂,能阻断线粒体能量代谢,诱导多种癌细胞凋亡。 | |||
T76787 |
Conatumumab
TRAIL-R2 mAb,AMG 655 |
TNF | Apoptosis |
Conatumumab (AMG 655) 是一种靶向人死亡受体 5 (DR5,TRAILR2) 的单克隆激动剂抗体 ,对长型 DR5 的 Kd 为 1 nM, 对短型 DR5 的 Kd 0.8 nM。Conatumumab 通过半胱天冬酶激活在多种肿瘤类型中诱导细胞凋亡。Conatumumab 可用于研究晚期实体肿瘤。 | |||
T24176 |
(-)-Irofulven
MGI-114,NSC-683863,MGI 114,HMAF,MGI114,Irofulven |
||
Irofulven is an agent of DNA-damaging and antitumor. It is used for the treatment of advanced solid tumors, including prostate, ovarian, and pancreatic cancers. | |||
T77120 | Opucolimab | ||
Opucolimab,一种针对PD-L1的重组人源化单克隆抗体,适用于合成抗体活性分子偶联物(Antibody-Drug Conjugates,ADCs)及晚期实体瘤研究。 | |||
T69759 | IACS-9439 | c-Fms | Tyrosine Kinase/Adaptors |
IACS-9439是一种CSF1R抑制剂,具有高效、选择性和口服活性,Ki值仅为1 nM。适用于研究晚期实体肿瘤。 | |||
T76929 | Betifisolimab | ||
Betifisolimab (MSB-2311) 是一种针对PD-L1免疫抑制配体的人源化单克隆抗体。该化合物展现出针对晚期实体瘤和血液恶性肿瘤研究的潜力。 | |||
T80217 |
BT1718
|
MMP | Proteases/Proteasome |
BT1718是一种针对MT1-MMP的双功能抗癌肽,通过MT1-MMP靶向肿瘤来传递细胞毒性有效载荷Mertansine。作为一种多肽-毒素偶联物,其KD值为3 nM。MT1-MMP在多种晚期实体肿瘤如三阴性乳腺癌(TNBC)和非小细胞肺癌中呈现过表达。 | |||
T77881 |
Tisotumab vedotin
|
||
Tisotumab vedotin是一种针对组织因子(tissue factor, TF)的抗体-药物偶联物(ADC),由全人源单克隆抗体(TF-011)与Monomethyl Auristatin E (MMAE)耦合而成,具有显著抗肿瘤活性,适用于晚期或转移性实体瘤的治疗研究。 | |||
T69963 |
Birabresib dihydrate
|
||
Birabresib dihydrate was initially developed by Mitsubishi Tanabe Pharma Corporation, but then was licensed by OncoEthix, privately held biotechnology company. OTX015 is a selective bromodomains: BRD2, BRD3, and BRD4 inhibitor and inhibits their binding to AcH4. Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and dif... | |||
T36648 | Tucatinib hemiethanolate | ||
Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib hemiethanolate has nanomolar activity against purified HER2 enzyme and is approximately 500-fold selective for HER2 versus EGFR in cell-based assays. Tucatinib selectively inhibits the receptor tyrosine kinase HER2 relative to EGFR[1].Tucatinib blocks proliferation and the phosphorylation of HER2 and its downstream effector, Akt in HER2 overexpressing cell lines. In the ... |